At Surgical Science Sweden AB’s Annual General Meeting today, the following, amongst other things, was decided:

• To adopt the Company’s and the Group’s income statements and balance sheets for the financial year 2024, as set out in the annual report. Those who served as Board members and CEOs were discharged from liability for the financial year 2024.
• The Board of Directors' proposal for disposition regarding the company's profit was approved. No dividend will be paid for the financial year 2024 and the funds at the disposal of the Annual General Meeting will be carried forward.
• Re-election of Board members Roland Bengtsson, Jan Bengtsson, Thomas Eklund, Henrik Falconer, Elisabeth Hansson, Åsa Bredin and Gisli Hennermark, in accordance with the Nomination Committee’s proposal. Gisli Hennermark was elected new Chairman of the Board of Directors.
• Remuneration to Board members shall, in accordance with the Nomination Committee’s proposal, be SEK 600,000 to the Chairman of the Board of Directors and SEK 200,000 to each of the other Board members, SEK 85,000 to the Chairman of the Audit Committee, SEK 45,000 to each of the other members of the Audit Committee, SEK 60,000 to the Chairman of the Remuneration Committee, and SEK 30,000 to each of the other members of the Remuneration Committee.
• Re-election, in accordance with the Nomination Committee’s proposal, of the registered auditing company KPMG AB. The authorized public accountant Daniel Haglund will be auditor in charge.
  
• To adopt the Board of Directors' proposal to implement a long-term incentive program for employees in the Group and executive management in Israel. The rationale of the incentive program is e.g. to contribute to higher motivation and commitment among the employees and to retain employees. The program comprises 370,000 warrants corresponding to a dilution of 0.73 percent. To enable the incentive program, the Annual General Meeting also resolved to issue 370,000 warrants to a subsidiary and to approve transfer of these warrants to participants of the program without consideration. Each warrant entitles the holder to subscribe for one (1) new share in the company. The subscription price of the share at the time of the utilisation of the warrant shall correspond to 120 percent of the Surgical Science share’s average volume-weighted closing price during the period from and including May 16, 2025 to and including May 30, 2025. The warrants can be exercised by notification of subscription for new shares during the period from and including June 14, 2028 to and including July 14, 2028.
• To adopt the Board of Directors' proposal to implement a long-term incentive program for executive management in Sweden. The rationale of the incentive program is e.g. to contribute to higher motivation and commitment among the employees and to retain employees. The program comprises 32,000 warrants corresponding to a dilution of 0.06 percent. To enable the incentive program, the Annual General Meeting also resolved to issue 32,000 warrants to a subsidiary and to approve transfer of these warrants to participants of the program without consideration. Each warrant entitles the holder to subscribe for one (1) new share in the company. The subscription price of the share at the time of the utilisation of the warrant shall correspond to 120 percent of the Surgical Science share’s average volume-weighted closing price during the period from and including May 16, 2025 to and including May 30, 2025. The warrants can be exercised by notification of subscription for new shares during the period from and including June 14, 2028 to and including July 14, 2028.
• Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on the issue of shares, corresponding in total to no more than 10 percent of the share capital.

Gothenburg, Sweden, May 15, 2025
Surgical Science Sweden AB (publ)
The Board of Directors

The press release, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

For further information, please contact:

Tom Englund, CEO
Telephone: +46-70-916 16 81
E-mail: tom.englund@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is reducing injuries incurred during care. Medical education and training are key, especially as a large part of the training can now be performed outside the operating room. Surgical Science is a world leader in the development of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psycho-motor skills and instrument handling before entering the clinical environment. Alongside its own products, Surgical Science works with simulation solutions for medical device companies that develop instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 330 employees. The company is headquartered in Gothenburg, Sweden, and has operations in Tel Aviv, Israel; Stockholm, Sweden; Seattle and Cleveland, US; and Cardiff, UK. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market. Certified Adviser is DNB Carnegie Investment Bank AB.

Attachments

Report from the Annual General Meeting of Surgical Science Sweden AB (publ)

Läs mer på MFN